Editorial: Resistant pathogens: from distribution to emerging therapies
- PMID: 37469429
- PMCID: PMC10352947
- DOI: 10.3389/fmicb.2023.1243067
Editorial: Resistant pathogens: from distribution to emerging therapies
Keywords: Extended-spectrum ß-lactamase (ESBL); Staphylococcus aureus; Staphylococcus pseudintermedius; antibiotic resistance; antifungal resistance; resistome; vaccine.
Conflict of interest statement
MM and PP-R are founders and stockholders of the biotechnology spin-off company Vaxdyn, which develops vaccines for infections caused by MDR bacteria. Vaxdyn had no role in the elaboration of this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Resistant pathogens: from distribution to emerging therapies
References
-
- O'Neill J. (2014). Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. London: Review on Antimicrobial Resistance. Available online at: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Ta... (accessed June 19, 2023).
-
- Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D. L., et al. . (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327. 10.1016/S1473-3099(17)30753-3 - DOI - PubMed
-
- WHO (2022). WHO Fungal Priority Pathogens List to Guide Research, Development And Public Health Action. Geneva: World Health Organization.
Publication types
LinkOut - more resources
Full Text Sources
